A Study to Understand How the Study Medicine (PF-06823859) Works in People With ActiveIdiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
- Conditions
- Myositis,
- Registration Number
- CTRI/2024/01/061439
- Lead Sponsor
- Pfizer Inc.
- Brief Summary
The purpose of the study is to understand how the study medicine PF-06823859 works in people with idiopathic inflammatory myopathies (DM and PM). These disorders cause inflammation that weakens the muscles that are important for movement and may also cause skin rash in people with DM.
This study is seeking participants who:
- Are 18 years of age or older.
- Have active DM or active PM.
- Are receiving a stable dose of 1 corticosteroid taken by mouth and/or 1 traditional immunosuppressant.
- Note: Corticosteroids and immunosuppressants are medicines that help reduce inflammation and may signal to the immune system not to attack the body.
Dermatomyositis (DM) is a rare disease that causes muscle inflammation that results in muscle weakness and low muscle stamina. Patients with DM have a characteristic skin rash. Polymyositis (PM) is a rare disease that involves mainly muscle inflammation resulting in muscle weakness, that can sometimes be painful. Patients with DM and PM may have trouble going up the steps, walking or getting to a standing position.
Some of the participants will receive the study medicine (PF-06823859) and some will receive placebo (which is similar to study medicine but contains no medicine in it).
The study medicine or placebo will be given as an intravenous (IV) infusion (directly into the veins), which takes about1 hour; every 4 weeks from Day 1 to Week 48 of the study. Both PF-06823859 and placebo and will be given at the study site.
The study will compare the experiences of people receiving study medication to those of the people who do not. This will help to see if PF-06823859 is safe and effective.
Participants will take part in this study for about 13 months. During this time, participants will have 16 study visits. These visits will be performed at the study site, but some study visits may be available at home or via mobile clinic if the study location participates in this option.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- All
- Target Recruitment
- 270
- Male or female adults (greater than equal to 18 years old) 2.
- Active dermatomyositis (DM) or polymyositis (PM) with age of onset: a) 18 years old 3.
- Must be receiving a stable dose of standard of care (SOC) background medications at the time of enrollment.
- Myositis due to non-Idiopathic inflammatory myopathies (non-IIM) 2.
- Existing diagnosis of inclusion body myositis (IBM) 3.
- Presence of immune-mediated necrotizing myositis (IMNM) 4.
- Myositis with end-stage organ involvement 5.
- Active bacterial, viral or fungal infections or hospitalizations for serious infections within 60 days prior to enrollment 6.
- Have cancer or a history of cancer within 5 years of screening 7.
- Significant current or prior disease conditions that may interfere with the response to or safety of the study medicine, including but not l limited to: 8.
- history of major organ transplant 9.
- acute coronary syndrome or any history of significant cerebrovascular disease within 24 weeks of screening 10.
- preexisting demyelinating disorder such as multiple sclerosis, or other severe neurological disorder 11.
- major surgery within 4 weeks of screening, or scheduled to occur during the study, excluding diagnostic surgery 12.
- history of any lymphoproliferative disorder such as Epstein Barr Virus, history of lymphoma, leukemia, or symptoms of current lymphatic or lymphoid disease 13.
- Clinically significant depression, suicidal ideation, or previous history of suicidal behaviors 14.
- Other medical or laboratory abnormality that may increase the risk of study participation 15.
- Previous administration with an investigational product (drug or vaccine) within 30 days or of the first dose of study medicine 16.
- Current use or incomplete appropriate washout period of any prohibited medication(s), including known exposure to anti-interferon beta (PF-06823859) or any type of anti-interferon beta therapy 17.
- Prior SOC medication that does not fulfill the criteria 18.
- Certain laboratory results from screening assessments that may interfere with study participation.
- Investigator site staff directly involved in the conduct of the study and their family members, site staff and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Total Improvement Score 0 to 100 with higher scores indicating a better outcome. 24 weeks outside of the United States (US) and 52 weeks in the US
- Secondary Outcome Measures
Name Time Method Change from baseline in Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score (CDASI-A) in participants with dermatomyositis (DM) Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score 0 to 100 with higher scores indicating a worse outcome. Only participants with baseline CDASI-A score more than 14 will be assessed. Change from baseline in Investigator Global Assessment severity scale (IGA) in participants with dermatomyositis Investigator Global Assessment severity scale 0 to 4 with higher scores indicating a worse outcome. Only participants with baseline IGA more than equal to 2 will be assessed Corticosteroid (CS) dose assessment Normalized Area Under the Curve (AUC) of corticosteroid dose Moderate change in Total Improvement Score Total Improvement Score 0 to 100 with higher scores indicating a better outcome. Change from baseline in Manual Muscle Testing - 8 designated muscles (MMT-8) Manual Muscle Testing (8 designated muscles) 0 to 150 with higher scores indicating a better outcome Change from baseline in Patient-Reported Outcomes Measurement Information System - Physical Function (PROMIS-PF) Patient-Reported Outcomes Measurement Information System - Physical Function 0 to 100 with higher scores indicating a better outcome Change from baseline in 5-D Itch Scale Score 5-D Pruritis Scale 5 to 25 with higher scores indicating a worse outcome. Only participants with baseline CDASI-A score more than 14 will be assessed. Change from baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Functional Assessment of Chronic Illness Therapy - Fatigue 0 to 52 with higher scores indicating a better outcome Response in corticosteroid tapering At least 50% reduction from baseline or reduction in corticosteroid (CS) dose to less than 7.5 mg/day at Week 52 for participants with baseline CS dose more than equal to 10 mg/day
Trial Locations
- Locations (4)
Dr Shenoy’s Care Private Limited Centre for Arthritis and Rheumatism Excellence ( CARE)
🇮🇳Ernakulam, KERALA, India
Institute of Neurosciences
🇮🇳Surat, GUJARAT, India
IPGME&R and SSKM Hospital
🇮🇳Kolkata, WEST BENGAL, India
Medanta-The Medicity - Medanta Institute of Education & Research (MIER)
🇮🇳Gurgaon, HARYANA, India
Dr Shenoy’s Care Private Limited Centre for Arthritis and Rheumatism Excellence ( CARE)🇮🇳Ernakulam, KERALA, IndiaDr Shenoy PadmanabhaPrincipal investigator9446567000drshenoy@drshenoycare.com